These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

448 related items for PubMed ID: 18636260

  • 1. Influence of conditioning regimens and stem cell sources on donor-type chimerism early after stem cell transplantation.
    Sugita J, Tanaka J, Hashimoto A, Shiratori S, Yasumoto A, Wakasa K, Kikuchi M, Shigematsu A, Miura Y, Tsutsumi Y, Kondo T, Asaka M, Imamura M.
    Ann Hematol; 2008 Dec; 87(12):1003-8. PubMed ID: 18636260
    [Abstract] [Full Text] [Related]

  • 2. Analysis of donor-type chimerism in lineage-specific cell populations after allogeneic myeloablative and non-myeloablative stem cell transplantation.
    Miura Y, Tanaka J, Toubai T, Tsutsumi Y, Kato N, Hirate D, Kaji M, Sugita J, Shigematsu A, Iwao N, Ota S, Masauzi N, Fukuhara T, Kasai M, Asaka M, Imamura M.
    Bone Marrow Transplant; 2006 May; 37(9):837-43. PubMed ID: 16547484
    [Abstract] [Full Text] [Related]

  • 3. Mesenchymal stem cells remain host-derived independent of the source of the stem-cell graft and conditioning regimen used.
    Bartsch K, Al-Ali H, Reinhardt A, Franke C, Hudecek M, Kamprad M, Tschiedel S, Cross M, Niederwieser D, Gentilini C.
    Transplantation; 2009 Jan 27; 87(2):217-21. PubMed ID: 19155975
    [Abstract] [Full Text] [Related]

  • 4. Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation.
    Blau IW, Schmidt-Hieber M, Leschinger N, Göldner H, Knauf W, Hopfenmüller W, Thiel E, Blau O.
    Ann Hematol; 2007 Aug 27; 86(8):583-9. PubMed ID: 17468869
    [Abstract] [Full Text] [Related]

  • 5. Rapid establishment of long-term culture-initiating cells of donor origin after nonmyeloablative allogeneic hematopoietic stem-cell transplantation, and significant prognostic impact of donor T-cell chimerism on stable engraftment and progression-free survival.
    Keil F, Prinz E, Moser K, Mannhalter C, Kalhs P, Worel N, Rabitsch W, Schulenburg A, Mitterbauer M, Greinix H.
    Transplantation; 2003 Jul 15; 76(1):230-6. PubMed ID: 12865815
    [Abstract] [Full Text] [Related]

  • 6. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED, Cioc A, Defor T, Dolan M, Weisdorf D.
    Biol Blood Marrow Transplant; 2009 Jan 15; 15(1):30-8. PubMed ID: 19135940
    [Abstract] [Full Text] [Related]

  • 7. A comparison between low intensity and reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for solid tumors.
    Conrad R, Remberger M, Cederlund K, Ringdén O, Barkholt L.
    Haematologica; 2008 Feb 15; 93(2):265-72. PubMed ID: 18245651
    [Abstract] [Full Text] [Related]

  • 8. [Application of sequential and quantitative monitoring of chimerism in allogeneic hematopoietic stem cell transplantation].
    Tang XW, Wu DP, Zhu ZL, Wang W, Sun AN, Qiu HY, Fu ZZ, Chang WR, Ruan CG.
    Zhonghua Xue Ye Xue Za Zhi; 2004 Feb 15; 25(2):78-81. PubMed ID: 14990044
    [Abstract] [Full Text] [Related]

  • 9. Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning.
    Valcárcel D, Martino R, Caballero D, Mateos MV, Pérez-Simón JA, Canals C, Fernández F, Bargay J, Muñiz-Díaz E, Gonzalez M, San Miguel JF, Sierra J.
    Bone Marrow Transplant; 2003 Mar 15; 31(5):387-92. PubMed ID: 12634730
    [Abstract] [Full Text] [Related]

  • 10. CD34+ cell dose, conditioning regimen and prior chemotherapy: factors with significant impact on the early kinetics of donor chimerism after allogeneic hematopoietic cell transplantation.
    Mohr B, Koch R, Thiede C, Kroschinsky F, Ehninger G, Bornhäuser M.
    Bone Marrow Transplant; 2004 Dec 15; 34(11):949-54. PubMed ID: 15489870
    [Abstract] [Full Text] [Related]

  • 11. Early complete donor hematopoietic chimerism in peripheral blood indicates the risk of extensive graft-versus-host disease.
    Balon J, Hałaburda K, Bieniaszewska M, Reichert M, Bieniaszewski L, Piekarska A, Pawłowski R, Hellmann A.
    Bone Marrow Transplant; 2005 Jun 15; 35(11):1083-8. PubMed ID: 15821766
    [Abstract] [Full Text] [Related]

  • 12. Comparison of donor chimerism following myeloablative and nonmyeloablative allogeneic hematopoietic SCT.
    Mickelson DM, Sproat L, Dean R, Sobecks R, Rybicki L, Kalaycio M, Pohlman B, Sweetenham J, Andresen S, Bolwell B, Copelan EA.
    Bone Marrow Transplant; 2011 Jan 15; 46(1):84-9. PubMed ID: 20305699
    [Abstract] [Full Text] [Related]

  • 13. Immune reconstitution following reduced-intensity transplantation with cladribine, busulfan, and antithymocyte globulin: serial comparison with conventional myeloablative transplantation.
    Saito T, Kanda Y, Nakai K, Kim SW, Arima F, Kami M, Tanosaki R, Tobinai K, Wakasugi H, Heike Y, Mineishi S, Takaue Y.
    Bone Marrow Transplant; 2003 Sep 15; 32(6):601-8. PubMed ID: 12953133
    [Abstract] [Full Text] [Related]

  • 14. [Second transplant from the same donor without conditioning for bone marrow aplasia after non-myeloablative hematopoietic stem cell transplantation for chronic myeloid leukemia].
    Ishikawa I, Miyamura K, Yamada M, Sasaki O, Harigae H, Kameoka J, Meguro K, Sasaki T.
    Rinsho Ketsueki; 2005 Dec 15; 46(12):1288-92. PubMed ID: 16447801
    [Abstract] [Full Text] [Related]

  • 15. Thiotepa improves allogeneic bone marrow engraftment without enhancing stem cell depletion in irradiated mice.
    Down JD, Westerhof GR, Boudewijn A, Setroikromo R, Ploemacher RE.
    Bone Marrow Transplant; 1998 Feb 15; 21(4):327-30. PubMed ID: 9509964
    [Abstract] [Full Text] [Related]

  • 16. Mixed chimerism achieved by a nonlethal conditioning regimen induces donor-specific tolerance to lung allografts.
    Li S, Salgar SK, Kurimoto Y, Yousem S, Pham SM.
    J Surg Res; 2008 May 15; 146(2):289-97. PubMed ID: 18314139
    [Abstract] [Full Text] [Related]

  • 17. Poor engraftment after allogeneic bone marrow transplantation: role of chimerism analysis in treatment and outcome.
    Au WY, Chan EC, Lie AK, Liang R, Leung AY, Ma SK, Kwong YL.
    Ann Hematol; 2003 Jul 15; 82(7):410-5. PubMed ID: 12750845
    [Abstract] [Full Text] [Related]

  • 18. A modified haploidentical nonmyeloablative transplantation without T cell depletion for high-risk acute leukemia: successful engraftment and mild GVHD.
    Guo M, Sun Z, Sun QY, Han Q, Yu CL, Wang DH, Qiao JH, Chen B, Sun WJ, Hu KX, Liu GX, Liu B, Zhao RC, Ai H.
    Biol Blood Marrow Transplant; 2009 Aug 15; 15(8):930-7. PubMed ID: 19589482
    [Abstract] [Full Text] [Related]

  • 19. Lymphocyte reconstitution following non-myeloablative hematopoietic stem cell transplantation follows two patterns depending on age and donor/recipient chimerism.
    Savage WJ, Bleesing JJ, Douek D, Brown MR, Linton GM, Malech HL, Horwitz ME.
    Bone Marrow Transplant; 2001 Sep 15; 28(5):463-71. PubMed ID: 11593319
    [Abstract] [Full Text] [Related]

  • 20. Mesenchymal stem cells are present in peripheral blood and can engraft after allogeneic hematopoietic stem cell transplantation.
    Villaron EM, Almeida J, López-Holgado N, Alcoceba M, Sánchez-Abarca LI, Sanchez-Guijo FM, Alberca M, Pérez-Simon JA, San Miguel JF, Del Cañizo MC.
    Haematologica; 2004 Dec 15; 89(12):1421-7. PubMed ID: 15590390
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.